Sales of Wegovy and Mounjaro Surge by 74 Percent Following New Reimbursement Policies in France

The pharmaceutical landscape in France has undergone a significant transformation following the government’s decision to integrate two high-profile weight-loss medications into the national reimbursement scheme. According to data presented on September 9, 2026, by the economic interest group Gers Data, the volume of sales for Wegovy (semaglutide, manufactured by Novo Nordisk) and Mounjaro (tirzepatide, manufactured by Eli Lilly) surged by 74 percent in retail pharmacies in the weeks immediately following the mid-June policy shift. This surge underscores both the high demand for advanced metabolic therapies and the substantial financial commitment now being shouldered by the French public health system to combat the rising prevalence of obesity and type 2 diabetes.

A Landmark Policy Shift: The June 15 Milestone

The pivotal moment in this market evolution occurred on June 15, 2026. On this date, the French health authorities officially authorized the reimbursement of Wegovy for the treatment of obesity and extended similar coverage for Mounjaro, covering both obesity management and the treatment of type 2 diabetes.

Prior to this inclusion, these medications were largely accessed through private, out-of-pocket payments, which restricted their use to those with the financial means to afford the high costs of these innovative GLP-1 and dual GLP-1/GIP receptor agonists. By transitioning these drugs into the reimbursable category, the government aimed to broaden access to clinical treatments for patients with high body mass index (BMI) scores or metabolic disorders, effectively integrating these pharmaceutical solutions into the standard of care for chronic weight management.

Analyzing the Surge: Statistical Insights from Gers Data

Gers Data, which provides comprehensive market tracking for the French pharmaceutical industry, conducted a comparative analysis of pharmacy sales across two distinct 11-week periods. The first period spanned the 11 weeks immediately preceding the June 15 decision, while the second period covered the 11 weeks following the implementation, extending until August 30, 2026.

The findings were striking: total volume across both drugs reached approximately 536,000 units delivered in retail pharmacies. This 74 percent increase is not merely a reflection of increased availability but an indicator of suppressed demand that had existed prior to the subsidy.

Of the total volume dispensed during the post-reimbursement period, approximately 60 percent of boxes were explicitly presented for state-subsidized reimbursement. Breaking this down by product, Mounjaro accounted for 72 percent of these reimbursed prescriptions—a likely reflection of its dual-indication status for both diabetes and obesity. Wegovy, positioned primarily for obesity management in this context, accounted for the remaining 28 percent. By the final week of the observation period (August 24–30), the proportion of boxes dispensed under the reimbursement scheme had climbed further, reaching 65 percent, suggesting that the public and prescribing physicians were increasingly utilizing the new administrative pathways.

Patient Demographics and Prescription Patterns

The data also offers a detailed profile of the patient population currently accessing these treatments. Demographic analysis reveals that women are the primary recipients of these prescriptions, accounting for 74 percent of all patients seeking Wegovy or Mounjaro at the pharmacy counter.

Age-based trends indicate that the therapies are most frequently dispensed to the middle-aged population. Patients aged 45 to 54 represent the largest cohort, at 26 percent, followed closely by the 55-to-64 age group at 24 percent, and the 35-to-44 group at 20 percent. This demographic distribution aligns with the clinical reality that the metabolic health risks associated with obesity often become most acute during these mid-life decades, where the cumulative effects of weight-related comorbidities, such as hypertension or early-stage insulin resistance, begin to manifest.

Impact on the Pharmaceutical Market and Therapeutic Classes

The meteoric rise of these medications has fundamentally altered the hierarchy of therapeutic classes in France. Gilles Paubert, General Delegate of Gers Data, noted that the inclusion of Novo Nordisk’s GLP-1 analog and Eli Lilly’s dual GLP-1/GIP receptor agonist has propelled their therapeutic class (A10S) to the forefront of market growth for reimbursable drugs.

Between August 2025 and August 2026, the antidiabetic agonist class (GLP-1 receptor agonists) generated an additional 221 million euros in sales, representing a 61 percent increase. This performance has eclipsed other historically high-growth areas, such as the interleukine inhibitors (L04C) category, which includes high-cost biologics like Dupixent and Skyrizi. The interleukine category grew by 25 percent, generating 211 million euros in additional sales. Other notable areas of growth included anti-neoplastic protein kinase inhibitors (+123 million euros) and SGLT2 inhibitors for diabetes (+87 million euros).

Financial Implications for the Public Health System

The decision to provide public coverage for these drugs represents a major fiscal commitment. In May 2026, prior to the official start of the program, Minister of Health Stéphanie Rist estimated that the annual cost of subsidizing these obesity treatments would reach approximately 100 million euros once the program reached full scale. This projection was based on a target population estimated at one million patients.

Economic analysts have begun to scrutinize whether the actual uptake, as evidenced by the 74 percent volume surge, will remain within these budgetary parameters. While the therapeutic benefits of these drugs—including potential reductions in heart disease, stroke, and diabetes-related hospitalizations—could theoretically offset long-term healthcare costs, the immediate, high-volume expenditure creates a significant short-term budgetary challenge for the French Social Security system.

Clinical Context and Future Outlook

The clinical success of semaglutide and tirzepatide in large-scale trials has been well-documented, showing significant weight loss and improvement in metabolic markers. However, the rapid increase in prescription volumes raises questions regarding the sustainability of supply chains. Both manufacturers have faced global shortages in the past, and the inclusion of France—a major European market—into the reimbursement net increases the pressure on production capacity.

Moreover, the healthcare community in France is currently navigating the shift from viewing obesity as a behavioral issue to treating it as a chronic, medically manageable condition. The role of the pharmacist has become increasingly central in this process, as they are the primary point of contact for patients adjusting to these injectable therapies. Pharmacists are currently tasked with ensuring correct dosage titration, monitoring for potential side effects, and managing the administrative complexities of the new reimbursement documentation.

Looking ahead, health policy experts suggest that the government may implement stricter monitoring of prescription criteria to ensure that the medication is reaching the patients most in need of clinical intervention, rather than those seeking cosmetic weight loss. The objective remains to balance patient access with the necessity of fiscal responsibility in a healthcare system that is already managing the competing demands of an aging population and a diverse, high-cost medicine pipeline.

As the French health authorities continue to monitor the impact of these policies, the trajectory of Wegovy and Mounjaro sales will serve as a bellwether for how modern Western healthcare systems integrate high-cost, high-efficacy metabolic drugs. The next phase of evaluation will likely focus on long-term clinical outcomes and the impact of these drugs on secondary health markers, which will ultimately determine the long-term viability of the current reimbursement model. For now, the data confirms that a massive, latent demand for these medications has been unlocked, marking a new era in the French public approach to metabolic disease management.